Micro-RNAs and ovarian cancer: The state of art and perspectives of clinical research

Gynecological Endocrinology

Volumn 30, Issue 4, 2014, Pages 266-271

  Gadducci, Angiolo ^a   Sergiampietri, Claudia ^a   Lanfredini, Nora ^a   Guiggi, Ilaria ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Biomarkers; Chemoresistance; Micro RNAs; Ovarian cancer; Prognosis

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CISPLATIN; MICRORNA; MICRORNA 192; MICRORNA 194; MICRORNA 200; MICRORNA 202; MICRORNA 205; MICRORNA 21; MICRORNA 30A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CARCINOGENESIS; CLEAR CELL CARCINOMA; CLINICAL RESEARCH; COLLOID CARCINOMA; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; HUMAN; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UPREGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; OVARY TUMOR; PROGNOSIS;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84897872316     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2013.871525     Document Type: Review

References (71)

1. Garofalo M, Croce CM. MicroRNAs: master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol 2011;51: 25-43.
2. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012;148: 1172-87.
3. Kim YK, Kim VN. Processing of intronic microRNAs. EMBO J 2007;26: 775-83.
4. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10: 126-39.
5. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet 2009;10: 704-14.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6: 857-66.
7. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010;16: 257-67.
8. Garofalo M, Quintavalle C, Romano G, et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012;12: 27-33.
9. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007;67: 8699-707.
10. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447: 1130-4.
11. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14: 2690-5.
12. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008;105: 7004-9.
13. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68: 425-33.
14. Dahiya N, Sherman-Baust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008;3:e2436.
15. Cao J, Cai J, Huang D, et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep 2013;30: 701-6.
16. Di Leva G, Croce CM. The role of microRNAs in the tumorigenesis of ovarian cancer. Front Oncol 2013;3:153.
17. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42: 1282-90.
18. Prislei S, Martinelli E, Mariani M, et al. MiR-200c and HuR in ovarian cancer. BMC Cancer 2013;13:72.
19. Chen Y, Zhang L, Hao Q. Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation. Cancer Cell Int 2013;13:86.
20. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep 2010;11: 670-7.
21. Creighton CJ, Gibbons DL, Kurie JM. The role of epithelialmesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res 2013;5: 187-95.
22. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 2010;42: 1282-90.
23. Prislei S, Martinelli E, Mariani M, et al. MiR-200c and HuR in ovarian cancer. BMC Cancer 2013;13:72.
24. Cochrane DR, Spoelstra NS, Howe EN, et al. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubuletargeting chemotherapeutic agents. Mol Cancer Ther 2009;8: 1055-66.
25. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006;12: 2774-9.
26. Liu Z, Liu J, Segura MF, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol 2012;228: 204-15.
27. Poliseno L, Tuccoli A, Mariani L, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006;108: 3068-71.
28. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. Embo J 2007;26: 3699-708.
29. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007;26: 2799-803.
30. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133: 647-58.
31. Frankel LB, Christoffersen NR, Jacobsen A, et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2007;283: 1026-33.
32. Wyman SK, Parkin RK, Mitchell PS, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009;4:e5311.
33. Peng DX, Luo M, Qiu LW, et al. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 2012;27: 1238-44.
34. Nagaraja AK, Creighton CJ, Yu Z, et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Endocrinol 2010;24: 447-63.
35. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008;20: 650-60.
36. Weichert W, Denkert C, Schmidt M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90: 815-21.
37. Zhang W, Wang Q, Yu M, et al. MicroRNA-145 Function as a cell growth repressor by directly targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat 2013. [Epub ahead of print].
38. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120: 635-47.
39. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21: 1025-30.
40. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67: 9762-70.
41. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007;67: 7713-22.
42. Wang Y, Hu X, Greshock J, et al. Genomic DNA copy-number alterations of the let-7 family in human cancers. PLoS One 2012;7: e44399.
43. Yeh YM, Chuang CM, Chao KC, Wang LH. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1a. Int J Cancer 2013;133: 867-78.
44. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor downmodulation. Proc Natl Acad Sci USA 2005;102: 18081-6.
45. Shedden KA, Kshirsagar MP, Schwartz DR, et al. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin Cancer Res 2005;11: 2123-31.
46. Thrall M, Gallion HH, Kryshio R, et al. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006;16: 166-71.
47. Calura E, Fruscio R, Paracchini L, et al. miRNA landscape in stage i epithelial ovarian cancer defines the histotype specificities. Clin Cancer Res 2013;19: 4114-23.
48. Lee H, Park CS, Deftereos G, et al. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 2012;10:174.
49. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359: 2641-50.
50. Vaksman O, Hetland TE, Trope' CG, et al. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol 2012;43: 2062-9.
51. Xiang Y, Ma N, Wang D, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2013. [Epub ahead of print].
52. Fu X, Tian J, Zhang L, et al. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett 2012;586: 1279-86.
53. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68: 425-33.
54. Kong F, Sun C, Wang Z, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technol Med Sci 2011;31: 543-9.
55. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008;68: 10307-14.
56. Liu N, Zhou C, Zhao J, Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest 2012;30: 577-82.
57. Shen L, Cui J, Liang S, et al. Update of research on the role of EZH2 in cancer progression. Oncol Targets Ther 2013;6: 321-4.
58. Hu S, Yu L, Li Z, et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010;10: 788-95.
59. Kuang Y, Cai J, Li D, et al. Repression of Dicer is associated with invasive phenotype and chemoresistance in ovarian cancer. Oncol Lett 2013;5: 1149-54.
60. Wang YQ, Guo RD, Guo RM, et al. MicroRNA-182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem 2013;114: 1464-73.
61. Huh JH, Kim TH, Kim K, et al. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br J Cancer 2013;109: 452-61.
62. Cittelly DM, Dimitrova I, Howe EN, et al. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther 2012;11: 2556-65.
63. Leskelä S, Leandro-García LJ, Mendiola M, et al. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer 2010;18: 85-95.
64. Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis 2013;2:e40.
65. Bu R, Uddin S, Bavi P, et al. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab Invest 2011;91: 124-37.
66. Zillhardt M, Park SM, Romero IL, et al. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res 2011;17: 4042-51.
67. Neijenhuis S, Bajrami I, Miller R, et al. Identification of miRNA modulators to PARP inhibitor response. DNA Repair 2013;12: 394-402.
68. Marchini S, Cavalieri D, Fruscio R, et al. Association between miR- 200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011;12: 273-85.
69. Hu X, Macdonald DM, Huettner PC, et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009;114: 457-64.
70. Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008;14: 2690-5.
71. Bentink S, Haibe-Kains B, Risch T, et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One 2012;7:e30269.